The Old Man and the Gene: Salmon, Science, and the $19 Billion Catch
What happened when the world’s first genetically modified food animal met the commercial market - and what does its failure tell us about the future of genomics in aquaculture?** AquaBounty Technologies spent 30 years developing and winning approval for the AquAdvantage salmon, the first gene-edited food animal approved for human consumption. By early 2025, it had shut down all operations and sold its patents. The story of what went wrong is as instructive as the science that got it there.
-----
In 1989, a small team of scientists at a company that would eventually become AquaBounty Technologies did something that had never been done before: they inserted the growth hormone gene from a Chinook salmon into an Atlantic salmon embryo, paired with a promoter sequence from the ocean pout that kept the growth hormone active year-round instead of only in spring and summer. The result was a fish that grew to market size in 16 to 18 months instead of the typical three years - roughly twice as fast, on approximately 25 percent less feed.
It was, by any measure, a remarkable piece of genomic engineering.
What followed was one of the longest and most expensive regulatory odysseys in the history of food biotechnology, a story of scientific achievement colliding with consumer skepticism, activist opposition, retail reluctance, and, ultimately, the simple mathematics of cash flow.
By March 2025, AquaBounty had sold its Canadian farms, its corporate intellectual property, its trademarks, and its patents for net proceeds of $1.9 million. A company that had spent more than three decades and hundreds of millions of dollars developing and commercializing the world’s first gene-edited food animal closed with $951,000 in cash equivalents on its balance sheet.
The salmon died. The science did not.
The Regulatory Marathon
AquaBounty first submitted data to the FDA in 1995. The agency approved the AquAdvantage salmon for human consumption in November 2015 - the first time the FDA had ever approved a genetically modified animal for the food supply. The decision came twenty years after the initial application and reflected an assessment that the fish was as safe to eat as any non-genetically
engineered Atlantic salmon, and no more likely to cause environmental harm given the company’s use of all-female, sterile fish raised in land-based, physically contained facilities.
Even that approval came with complications. A rider attached to a federal spending bill signed in December 2015 barred the salmon’s import into the U.S. until the FDA mandated labeling for the genetically modified product. The import alert was not deactivated until March 2019. The commercial window that opened was narrow.
AquaBounty’s Indiana facility - a recirculating aquaculture system near Albany, Indiana - began operations in 2019 and produced product revenue of $2.5 million in 2023. In July 2024, the company sold the Indiana facility to cover operating costs. By December 2024, it wound down its last Canadian farm. By March 2025, the patents and trademarks were gone.
The total net loss for 2024 alone was $149.2 million, swelled by $129.8 million in asset impairment charges.
What the Failure Reveals
AquaBounty’s collapse was not a scientific failure. The AquAdvantage salmon performed as designed. The biology worked. The regulatory pathway, while extraordinarily slow, was ultimately navigated. What failed was the commercial ecosystem around the product.
Retail adoption was limited. Major U.S. grocery chains declined to carry the fish, citing consumer uncertainty about genetically modified seafood. The “Frankenfish” label - coined by former Alaska Senator Mark Begich in 2010 and amplified by environmental advocacy groups throughout the regulatory process - proved more durable than the company’s marketing budget. Wild Alaska salmon interests, with significant commercial and political stakes in the outcome, lobbied aggressively against the product.
The company also faced structural cost challenges inherent to land-based aquaculture. Recirculating aquaculture systems - the enclosed, tank-based facilities that AquaBounty used to contain its modified fish - require significant capital investment and carry higher operating costs than conventional net-pen ocean farming. Without the retail volume to justify those costs, the economics never scaled.
The $19 Billion Market That Remains
What AquaBounty could not commercialize is a market that keeps growing without it.
The global salmon aquaculture market was valued at $19.1 billion in 2024 and is projected to reach $44.4 billion by 2034, according to market research firm GMInsights. Norway, Chile, and the United Kingdom dominate production, collectively accounting for the vast majority of farmed Atlantic salmon. Genomic selection - traditional breeding accelerated by DNA marker analysis -
has already produced commercial salmon that grow roughly twice as fast as their wild ancestors, with dramatically improved disease resistance and feed conversion efficiency.
The aquaculture genetics market, which encompasses genomic selection, marker-assisted selection, and genome editing across salmon, shrimp, tilapia, and other farmed species, is projected to reach $683.94 million by 2029 at a 9.4 percent compound annual growth rate.
The Roslin Institute in Scotland - the same research institution that produced Dolly the cloned sheep - is a global leader in salmon genomics research. Hendrix Genetics, better known for poultry and swine, operates a salmon genetics division. SalMar, Mowi (formerly Marine Harvest), and Cermaq - the Norwegian giants that dominate global salmon farming - run sophisticated genomic selection programs that have steadily compressed production timelines and improved disease resistance without transgenic modification.
CRISPR-based gene editing is advancing in aquaculture research settings. Sterile salmon that cannot interbreed with wild populations - achieved through gene editing rather than physical sterilization - are in development. Disease resistance edits targeting sea lice and viral infections are being studied. The tools AquaBounty pioneered, at some cost to itself, are moving forward under different regulatory and market conditions.
The Lesson
AquaBounty was right about the science and early on the timeline. It was wrong about the market's readiness to accept a product labeled as genetically engineered, sold through retail channels that were not yet comfortable with the GMO designation, in a category where the incumbent had both economic and cultural advantages.
But history is full of technologies that arrived before the world was ready for them.
Electric cars existed long before Tesla.
Artificial intelligence spent decades in research labs before becoming a trillion-dollar industry.
The internet was commercially available years before it transformed the global economy.
The question was never whether biology could be engineered. AquaBounty proved that it could.
The question was whether society, regulators, retailers, and consumers were prepared for the implications.
The answer, at least in 2015, was no.
The next wave of genomics-enhanced aquaculture will likely avoid many of the obstacles AquaBounty faced. CRISPR-based edits are regulated differently in many jurisdictions. Genomic selection programs improve animals without introducing foreign DNA. Future products may reach consumers without ever carrying the baggage that accompanied the GMO debate.
AquaBounty may ultimately be remembered not as the company that commercialized the first genomically engineered food animal, but as the company that demonstrated what was possible.
The salmon failed.
The idea did not.
And in a world that will need dramatically more protein, produced with fewer resources and lower environmental impact, that idea is likely worth far more than the company that first proved it.
-----
Aquaculture genomics sits within GMG’s Animals category, where DNA-driven improvements to farmed species are reshaping global food supply chains. AquaBounty Technologies (AQB:NASDAQ) is currently a shell company with no operating salmon production. Key aquaculture genetics players: Hendrix Genetics (private, Netherlands), Mowi (MOWI:Oslo Stock Exchange), SalMar (SALM:Oslo Stock Exchange), Cermaq (private, subsidiary of Mitsubishi Corporation).